ANTIMICROBIAL AND ANTIOXIDANT STUDIES OF VERNONIA AMYGDALINA
Foo Rui Qing, Manogaran Elumalai, Gabriel Akyirem Akowuah
Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara Gading, UCSI Heights, 56000 Kuala Lumpur, Malaysia
Keywords: V. amygdalina; total phenolic; total saponin; free radical; antimicrobial
Abstract

In this study, the ethanol extract (EE), ethyl acetate extract (EAE), aqueous decoction extract (ADE) and aqueous maceration extract (AME) of Vernonia amygdalina leaves were subjected to total phenolic (TP) and total saponin (TS) content determination, in vitro radical scavenging activity and antimicrobial susceptibility testing (AST). The TP contents in order of decreasing quantities were 63.044, 38.834, 53.148 and 39.391 mg of gallic acid equivalents (GAE) per g dry extract for EE, EAE, ADE and AME, respectively. The TS assay revealed that the EAE extract possessed the highest TS content with a value of 952.037 mg of diosgenin equivalents (DE) per g dry extract. This was followed by the EE, ADE and AME extract with TS content of 841.370, 159.741 and 118.444 mg diosgenin equivalents (DE) per gram dry extract. The DPPH assay revealed that the ADE had the highest DPPH radical scavenging activity with an IC50 value of 501.207 µg/ml. This was followed by EE, EAE and AME with IC50 values of 636.010, 658.277 and 1368.929 µg/ml, respectively. The ADE also exhibited the highest ABTS radical scavenging activity with an IC50 value of 3195.083 µg/ml. In the subsequent order of decreasing ABTS scavenging activity was AME, EE and EAE extracts with IC50 values of 4142.156, 5508.517 and 6547.940 µg/ml. The results of AST showed that the test organisms E. coli O157:H7 and Y. enterocolitica were resistant towards the V. amygdalina extracts tested. Only the AME extract possesses a MIC value of 31.25 mg/ml against Y. enterocolitica. The data obtained reaffirms V. amygdalina’ spontential as a source of dietary antioxidants and provides information on the the suitability of V. amygdalina against E. c.oli O157:H7 and Y. enterocolitica.

Article Information

Identifiers and Pagination:
Year:2014
Volume:6
First Page:332
Last Page:343
Publisher Id:19204159.6:4.2014
Article History:
Received:June 22, 2014
Accepted:July 12, 2014
Collection year:2014
First Published:October 1, 2014


© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license. You are free to: Share — copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. No additional restrictions You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
Editor in Chief
Prof. Dr. Cornelia M. Keck (Philipps-Universität Marburg)
Marburg, Germany

Bibliography

Welcome to the research group of Prof. Dr. Cornelia M. Keck in Marburg. Cornelia M. Keck is a pharmacist and obtained her PhD in 2006 from the Freie Universität (FU) in Berlin. In 2009 she was appointed as Adjunct Professor for Pharmaceutical and Nutritional Nanotechnology at the University Putra Malaysia (UPM) and in 2011 she obtained her Venia legendi (Habilitation) at the Freie Universität Berlin and was appointed as a Professor for Pharmacology and Pharmaceutics at the University of Applied Sciences Kaiserslautern. Since 2016 she is Professor of Pharmaceutics and Biopharmaceutics at the Philipps-Universität Marburg. Her field of research is the development and characterization of innovative nanocarriers for improved delivery of poorly soluble actives for healthcare and cosmetics. Prof. Keck is executive board member of the German Association of Nanotechnology (Deutscher Verband Nanotechnologie), Vize-chairman of the unit „Dermocosmetics“ at the German Society of Dermopharmacy, active member in many pharmaceutical societies and member of the BfR Committee for Cosmetics at the Federal Institute for Risk Assessment (BfR).

Journal Highlights
Abbreviation: J App Pharm
doi: http://dx.doi.org/10.21065/19204159
Frequency: Annual 
Current Volume: 9 (2017)
Next scheduled volume: December, 2018 (Volume 10)
Back volumes: 1-9
Starting year: 2009
Nature: Online 
Submission: Online  
Language: English

Subject & Scope
  • Pharmaceutics
  • Physical Pharmacy 
  • Dosage Forms Science 
  • Pharmaceutical Microbiology & Immunology 
  • Industrial Pharmacy 
  • Bio-Pharmaceutics 
  • Pharmaceutical Chemistry 
  • Pharmaceutical Instrumentation 
  • Medicinal Chemistry 
  • Pharmacognosy 
  • Physiology &Histology 
  • Anatomy & Pathology 
  • Pharmacology & Therapeutics 
  • Pharmacy Practice 
  • Pharmaceutical Mathematics   
  • Biostatistics 
  • Dispensing 
  • Community Social & Administrative Pharmacy 
  • Hospital Pharmacy 
  • Clinical Pharmacy 
  • Pharmaceutical Quality Management 
  • Forensic Pharmacy 
  • Pharmaceutical Technology 
  • Pharmaceutical Management & Marketing

Consortium Publisher is an online publisher that enjoys global presence with International Journals

Follow Us

©2009 - 2019 Consortium Publisher Canada

Contact Info

6252 Lisgar Dr Mississauga Ontario L5N7V2 Canada
+1 (647) 526-0885
office@consortiumpublisher.ca
http://www.consortiumpublisher.ca/